Compare CVS Health Corp (CVS) vs GameStop Corp. (GME) Price & Performance

CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.

The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.

GME trades at $22.03, up 1.61% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue for 2025 was $3.82 billion, with net income of $131.3 million and a profit margin of 3.43%. Recent news highlights the proposed eBay acquisition and a robust EBITDA outlook exceeding $600 million for fiscal 2026.

The outlook is mixed; fundamental improvements in profitability and strategic moves like the eBay bid offer potential upside, but bearish technicals and a majority hold rating from analysts suggest caution. Key risks include execution of the acquisition, competitive pressures from digital game distribution, and reliance on collectibles growth.